کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5858882 1562173 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
ReviewThe fetal safety of Levetiracetam: A systematic review
موضوعات مرتبط
علوم زیستی و بیوفناوری علوم محیط زیست بهداشت، سم شناسی و جهش زایی
پیش نمایش صفحه اول مقاله
ReviewThe fetal safety of Levetiracetam: A systematic review
چکیده انگلیسی

ObjectiveTo systematically review the available published evidence on the fetal safety of Levetiracetam with focus on birth defects.ResultsEight studies met the inclusion criteria; five pregnancy registries and one population based cohort study. A total of 27 major congenital malformations were reported among 1213 Levetiracetam monotherapy - exposed pregnant women, yielding an overall major malformation rate of 2.2% (27/1213) [95% confidence interval of 1.53-3.22]. In contrast, Levetiracetam polytherapy was associated with significantly higher malformation rate of 6.3% (34/541) [95% CI of 4.53-8.65] (P < 0.001). Additionally 2 studies investigating child neurodevelopment in Levetiracetam - exposed children revealed that the measured achievements were well above those children exposed to valproic acid, and similar to unexposed controls.ConclusionsThe current evidence suggests that the overall risk of major malformation after first trimester exposure to Levetiracetam is within the population baseline risk of 1-3%, with no apparent adverse effects on long term child development.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Reproductive Toxicology - Volume 46, July 2014, Pages 40-45
نویسندگان
, , ,